Lamotrigene and vigabatrin in intractable seizures in children

Area of Science:

• Pediatric Neurology
• Clinical Pharmacology

Background:

• Intractable seizures in children pose significant management challenges.
• Add-on antiepileptic drug (AED) therapy is often necessary for refractory epilepsy.
• Limited data exists comparing the efficacy of specific AEDs in diverse pediatric seizure types.

Purpose of the Study:

• To evaluate the efficacy of vigabatrin (VGB) and lamotrigine (LTG) as add-on therapy in children with intractable seizures.
• To determine the optimal drug selection based on seizure type and neurological presentation.

Main Methods:

• A cohort of 27 children (5 months - 14 years) with intractable seizures received either VGB or LTG as add-on therapy.
• Drug selection was guided by seizure type and neurological abnormalities; progressive disorders were excluded.
• Diagnostic workup included EEG, CT head scans, and metabolic assessments.

Main Results:

• Vigabatrin (VGB) demonstrated highest efficacy in seizures associated with tuberous sclerosis.
• VGB was consistently effective for infantile spasms (IS) and tonic-clonic (TC) seizures.
• Lamotrigine (LTG) proved effective for complex partial seizures (CPS) and TC seizures with myoclonus.

Conclusions:

• Both VGB and LTG are valuable add-on therapies for pediatric intractable epilepsy.
• Seizure type and underlying neurological conditions should guide the selection between VGB and LTG.
• VGB is particularly beneficial for IS and TC seizures, while LTG is effective for CPS and myoclonic TC seizures.